

VPA10774/027/003

**Rycarfa 100 mg tablets for dogs**

| Variation             | Summary   | Date     |
|-----------------------|---|----------|
| Vet - C1              | VNRA - Vet - C1 - - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)   | 31/03/26 |
| Vet - B44 a)          | VNRA - Vet - B44 a) - - Vet - B44 a) - Submission of a Ph. Eur. CEP for:— active substance;— starting material, reagent or intermediate used in the manufacturing process of the active substance;— excipient - Updated certificate   | 28/11/25 |
| Vet - A2              | VNRA - Vet - A2 - - Vet - A2 Administrative changes - Change in the (invented) name of the veterinary medicinal product   | 30/09/25 |
| Vet - G.I.18          | VRA-S - Vet - G.I.18 - - Vet - G.I.18 - One-off alignment of the product information with version 9.0* of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products authorised in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004   | 08/08/25 |
| Vet - C6              | VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17   | 01/12/23 |
| Vet - B47 d)          | VNRA - Vet - B47 d) - d) To reflect compliance with the Ph. Eur. by removing reference to the internal test method and test method number - B47d) Changes to the quality part of the dossier: Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State: — to reflect compliance with the Ph. Eur. by removing reference to the internal test method and test method number   | 06/03/23 |
| Vet - B44(Do not use) | VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient | 07/12/22 |
| B.I.b.2.a             | IA - B.I.b.2.a - a) Minor changes to an approved test procedure - B.I.b.2.a - QUALITY CHANGES - ACTIVE SUBSTANCE - Control of active substance - Change in  | 03/03/22 |

|  |   |  |
|--|---|--|
|  | test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Minor changes to an approved test procedure |  |
|--|---|--|